{"id":68769,"date":"2024-10-03T16:45:53","date_gmt":"2024-10-03T14:45:53","guid":{"rendered":"https:\/\/www.ipsen.com\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/"},"modified":"2024-10-11T12:08:31","modified_gmt":"2024-10-11T10:08:31","slug":"nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864","status":"publish","type":"statements","link":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/","title":{"rendered":"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine)"},"content":{"rendered":"\n<p>Ce m\u00e9dicament essentiel, ainsi que toutes les activit\u00e9s associ\u00e9es, vont \u00eatre transf\u00e9r\u00e9s \u00e0 Eton Pharmaceuticals \u00e0 la suite de la signature d\u2019un accord de transfert d\u2019actif, qui devrait \u00eatre conclu \u00e0 la fin de l\u2019ann\u00e9e 2024.<\/p>\n\n\n\n<p>Pour Ipsen comme pour Eton Pharmaceuticals, notre priorit\u00e9 sera de garantir l\u2019approvisionnement continu d\u2019Increlex tout au long de la p\u00e9riode de transition. Pour plus d\u2019informations, contactez-nous depuis la page <a title=\"\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=NPAMeQ_fjFUcYlQvYfNHILrcwZAfGSQvvoiqT_6mOhpBjQQCHcqYjY-63P4agQc7_t8_Sz37Do8PzYLGDA15Lgxn5oPkrSznsJHlmH701IUm3TrENboQs9BCJXWH_f1b\" target=\"_blank\" rel=\"nofollow noopener\"><u>www.ipsenmedicalinformation.com<\/u><\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OGQ5OTQ1MTEtODRjNC00OGFiLWEzMjktMTU1OWU1ZDRkYmUwLTEyNjgxMTY=\/tiny\/Ipsen-Pharma.png\" alt=\"\"\/><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[3544,3551],"tags":[],"class_list":["post-68769","statements","type-statements","status-publish","has-post-thumbnail","hentry","category-corporate-mediastatement-fr","category-rare-diseases-mediastatement-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-11T10:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/\",\"name\":\"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg\",\"datePublished\":\"2024-10-03T14:45:53+00:00\",\"dateModified\":\"2024-10-11T10:08:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/","og_locale":"fr_FR","og_type":"article","og_title":"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global","og_url":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/","og_site_name":"Global","article_modified_time":"2024-10-11T10:08:31+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/","url":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/","name":"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine) - Global","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg","datePublished":"2024-10-03T14:45:53+00:00","dateModified":"2024-10-11T10:08:31+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2024\/10\/03165047\/Thumbnail_IS_1082x620pix_200ko-max_FR.jpg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/statement\/nouvelle-information-importante-a-lattention-des-professionnels-de-sante-et-des-patients-concernant-la-solution-injectable-increlex-mecasermine-2957864\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Nouvelle information importante \u00e0 l\u2019attention des professionnels de sant\u00e9 et des patients concernant la solution injectable Increlex\u00ae (m\u00e9casermine)"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/68769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/statements"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/68769\/revisions"}],"predecessor-version":[{"id":69494,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/statements\/68769\/revisions\/69494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/68773"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=68769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=68769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=68769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}